Alirocumab and Reverse Cholesterol Transport

• Status: Completed
• Trial end date: 2018-07-30
• Target enrollment: 0
• Participant gender: All

Summary

Alirocumab is an injectable treatment for elevated blood cholesterol. The hypothesis of this study is that it also increases cholesterol excretion from the body into the stool, a process sometimes called reverse cholesterol transport. A cholesterol metabolic study will be done before and after 6 weeks of alirocumab treatment. If alirocumab increases reverse cholesterol transport, it is possible that this action provides additional protection from cardiovascular disease.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Washington University School of Medicine
• Treatments: Antibodies, Monoclonal

Criteria

Inclusion Criteria:

• Healthy or with stable medical or surgical illnesses

• LDL>100 mg/dl.

Exclusion Criteria:

• Triglycerides>250

• Taking drugs affecting lipid metabolism

• Elevated liver function tests

• Diabetes mellitus

• A1c 6.5% or greater

• Pregnant

• Breastfeeding

• Desire for conception in either sex.